Antibody–Drug Conjugate Platform

Antibody–drug conjugates (ADCs) enable targeted delivery of cytotoxic drugs to cancer cells while sparing healthy cells, thereby reducing the side effects associated with traditional chemotherapy. ADCs also increase drug efficacy by enhancing the specificity and potency of the drug. Additionally, ADCs have shown promising results in treating various types of cancer, including breast, lung, and hematologic malignancies, leading to approval for clinical use of ADCs from regulatory agencies.

Our extensive expertise covers all of the critical steps involved in the development of ADCs. With our knowledge and capabilities, we can assist you in the following areas.

  • Target expression analysis: We analyze target expression levels in both tumor and normal tissues, ensuring an understanding of tissue cross-reactivity.
  • Impact of target levels and heterogeneity: We evaluate the impact of target expression levels and heterogeneity on ADC efficacy and selectivity.
  • Target occupancy: Our platform allows us to assess target occupancy to determine the optimal dosing strategy.
  • Drug-to-antibody ratio (DAR) and dose response correlations: We investigate the relationship between DAR, dose response, and efficacy in vitro and ex vivo.
  • Internalization/degradation: We study the internalization and degradation kinetics of ADCs to better understand their mechanisms of action.
  • Cytotoxic activity: Our services include assessing the cytotoxic activity of ADCs in vitro and in vivo.
  • Mode of action analysis: We elucidate the mode of action of ADCs, providing insights into their therapeutic potential.
  • Enhanced permeability and retention (EPR) and bystander effect: We evaluate the impact of EPR and bystander effect, essential factors for effective ADC delivery and efficacy.
  • Biomarker strategy: We assist in developing a biomarker strategy to identify patients who are most likely to respond to ADC treatment.
  • Antigen expression level: We analyze antigen expression levels to optimize target selection and patient stratification.
  • Toxophore sensitivity markers: We identify toxophore sensitivity markers to assess potential toxicities associated with ADC treatment.
  • Indication profiling: We provide indication profiling to guide the selection of appropriate disease indications for ADC development.
  • PK/PD assessment: We conduct PK/PD assessments to understand the pharmacokinetics and pharmacodynamics of ADCs

With our comprehensive capabilities, we can support you throughout the entire ADC development process, ensuring the success of your therapeutic candidates.

In vivo characterization of ADCs (Golfier, et al., Mol Cancer Ther, 2014).